本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
【2025年4月23日，鹿兒島出水】筑波科技日本辦事處於4月15日在鹿兒島縣出水市揭牌，並與出水市政府簽署合作備忘錄 (MOU)，攜手推動智慧醫療與半導體應用。由出水市市長椎木伸一與筑波科技董事長許深福代表簽署，鹿兒島縣知事塩田康一與外交部駐福岡總領事陳銘俊擔任見證人，象徵台日政府企業合作新階段。 筑波科技長期深耕智慧醫療、半導體測試與AI演算，以日本為據點邁向國際。出水市市長椎木伸一致詞表示：「筑波科技是首家在本市設立據點的台灣企業。此機緣源於一隻『迷路的鶴』，透過台灣野鳥保育協會與本市鶴博物館交流，於台灣筑波舉辦野鳥攝影展、台灣青少年網球賽『筑波木笑盃』等，期待攜手促進共同成長。」筑波科技董事長許深福亦分享：「我們將以出水市為基地，推廣筑波科技智慧醫療與半導體技術，為日本科技與健康作出貢獻。」開幕典禮上，筑波系統總經理申義龍亦強調：「筑波系統致力於第三代半導體及太赫茲晶圓與材料檢測方案，將與日本半導體策略夥伴聯盟，拓展測試技術商機。」 現場貴賓亦針對合作方向發表見解。外交部駐福岡辦事處處長陳銘俊指出：「日本半導體核心重鎮位於九州，筑波科技設立據點展現其技術實力，代表台灣尖端科技進入日本的指標性意義。台日兩國在產業鏈上高度互補，未來合作潛力無限。」鹿兒島縣出水商工會議所會頭竹之下良二分析：「今天的開幕典禮令我深受感動，筑波科技的先進技術將對出水市的發展帶來深遠影響。」 智慧醫療的推動則由出水中央高等學校理事長倉田彰分享洞見，與筑波科技合作可提升護理科的技術啟發與教學資源，深化學生對智慧醫療的理解與應用，助於培育在地醫療科技人才，擴大醫療照護場域應用在教育界的影響力。 聯絡筑波科技 筑波科技股份有限公司ACE Solution, Co., Ltd. 地址：新竹縣竹北市台元街28號2樓之1 電話：03-5500909 電子郵件：service@acesolution.com.tw 網站：https://www.acesolution.com.tw/en/index/ 關於筑波科技（ACE Solution） 筑波科技（https://www.acesolution.com.tw/en/index/）成立於2000年，位於台灣新竹，在中國蘇州和深圳設有分公司。我們的使命是提供訂製的測試解決方案，以滿足電氣元件、設備和系統製造商的客戶需求，通過合作夥伴提供技術解決方案。我們專注於射頻、毫米波和太赫茲領域，擁有專業的技術支援團隊，提供專業、創新和多功能的綜合技術和解決方案。
TAIPEI, Sept. 11, 2024 /PRNewswire/ -- The High-Value Biomaterials Research and Commercialization Center (HBRCC) at "National Taipei University of Technology" (NTUT) on July 26 held an international forum at the 2024 Bio Asia-Taiwan. The event gathered renowned biomaterial experts from across the globe, including Professor Takanori Ichiki from Tokyo University, Professor Yasuhiko Tabata from Kyoto University, Professor Yu-Chen Hu from "National Tsing Hua University", Professor Haytam Kasem from Azrieli College of Engineering Jerusalem, Professor Maziar Ramezani from Auckland University of Technology, and Deputy Director Lun-De Liao of the Institute of Biomedical Engineering and Nanomedicine (IBEN) at "National Health Research Institutes" (NHRI). Presided over by HBRCC Director Hsu-Wei Fang, the forum focused on models for international collaboration in biomaterials and sharing of experiences in industry-academia cooperation by the attending experts, with the aim of strengthening cross-border exchanges and jointly advancing research in the field of biomaterials. Leading professors from across the globe are pictured at the NTUT forum on the latest trends in biomaterial development and commercialization. (Photo courtesy of NTUT) NTUT and NHRI Ink MOU on Deepening Collaboration to Jointly Promote Taiwan's Biomedical IndustryAt the event, experts witnessed the signing of a memorandum of understanding (MOU) between NTUT and NHRI to promote academic and talent exchanges and to jointly advance technology transfer. Director Hsu-Wei Fang stated that the HBRCC has been working closely with NHRI in technology transfer projects, with successes including patents on an artificial tear solution in Japan and Taiwan, as well as assisting the NHRI in planning the commercialization of the research outcome. Director Fang expressed hopes that the MOU will spark new opportunities in Taiwan's biomaterials field. IBEN Director Lun-De Liao said that the NHRI is Taiwan's leading medical and biomedical research institute, and that the MOU with NTUT's HBRCC will bring closer collaboration in technical research, talent cultivation and technology transfer, bringing new momentum to joint efforts on propelling biomedical research and academia-industry collaborations. 3P Model to Further Enhance Technology Transfer and Development of Taiwan's Biomaterial IndustryDirector Hsu-Wei Fang stated that assisting professors in commercializing their findings into products has been a perennial question at his institution, which is in particularly challenging in biomedicine due to regulatory, safety, and efficacy considerations. He also noted that many countries and universities have different approaches to technology transfer. Deputy Director Lun-De Liao stated that the 3P (Public-Private Partnerships) model can potentially transform the mindset on academia-industry collaborations, bring greater benefits to both sides and advance Taiwan's biomaterials industry. Deputy Director Liao also expressed hopes to drive Taiwan's industry development with the 3P model. Taiwan, Japan, Israel, New Zealand to Strengthen Exchanges, Competitiveness Leveraging Taiwan's Industry AdvantagesProfessor Kasem suggested that international exchanges could start with joint authorship of papers between researchers of Israel and Taiwan, and later progress to joint efforts at securing patents to attract commercialization opportunities. On education, the two sides could establish joint courses to keep students abreast of global academic and industry trends as well as enhance their global vision and hands-on capabilities. Professor Maziar Ramezani recommended Taiwan to work with top global institutions and participate in global research networks, as well as ink bilateral agreements with countries excelling in biomedical research to deepen collaborations and elevate Taiwan's competitiveness. He also recommended Taiwan to leverage its advantages in the semiconductor and electronics sectors to gain an edge in the biomedical field. Professor Ichiki stated that Japan and Taiwan have been collaborating in the semiconductor sector, and that Taiwan's long-standing focus on nanotechnology will be key to advancing its biomedical industry and deepening collaboration with Japan. Professor Ichiki emphasized that students should familiarize themselves with domain knowledge to lower obstacles to academic-industry collaborations as well as broaden their resources and professional networks. In conclusion, Professor Yu-Chen Hu stated that most of the industry-academia collaborations in Taiwan are small-scale and mainly focused on addressing specific industry bottlenecks, and that such efforts should scale up to larger projects to better encourage joint development of innovative technologies or new drugs. However, he said that despite Taiwan's strengths in R&D, its biomanufacturing capabilities lags behind South Korea, China, and Singapore. To address this concern, strengthening biomanufacturing should be prioritized to ensure that Taiwan has the domestic capacity to develop and manufacture drugs. NTUT's HBRCC Hoping for New Global Horizons Through International CollaborationDirector Fang stated that founded during the Japanese occupation, NTUT is a century-old institution and that 10% of alumni currently hold leadership positions in Taiwan's publicly traded companies. He said that the university emphasizes both theory and practice as well as focuses on achieving technology transfer, adding that further improvements in resource integration, market insights are needed to accelerate development and build new Taiwanese brands. Noting that the HBRCC is well experienced in technology transfer, Director Fang said that he is looking forward to collating the attending experts' insights and forming closer international collaborations to jointly open new horizons in the global biomedical industries.
International co-production streaming on TaiwanPlus, spotlighting Taiwan's warmth, hospitality, and cross-cultural storytelling TAIPEI, Sept. 24, 2025 /PRNewswire/ -- Ishida, a 33-year-old Japanese backpacker, has spent the past five years traveling across Japan with a handwritten sign that reads "May I Stay Tonight?" His journey is now the focus of May I Stay Tonight, a spin-off of Fuji TV's long-running documentary series "The Nonfiction," which has aired for more than 30 years. Ishida, a 33-year-old Japanese backpacker, has spent the past five years traveling across Japan with a handwritten sign that reads “May I Stay Tonight?” Yojiro Nishimura, Chief Producer of "The Nonfiction," noted in relation to this collaboration: "This documentary marks the first collaboration between Fuji TV and TaiwanPlus. We chose to feature the story of Mr. Ishida—also known as "Schlaf Ishida"—who has spent more than five years traveling across Japan with a simple sign that reads "May I stay tonight?", relying on the kindness of strangers to offer him a place to stay." Eric Yang, Head of Program Department at TaiwanPlus, went on to say, "This collaboration shows how international co-productions can bring out the charm and spontaneity of stories that resonate across cultures. We are delighted to work with Fuji TV to bring this program to audiences in Japan, Taiwan, and around the world." The Taiwan special of Fuji TV's "May I Stay Tonight?" is now available on the TaiwanPlus website and official TaiwanPlus YouTube channel. About TaiwanPlus TaiwanPlus is the premier global provider of English-language news and infotainment from Taiwan — offering trustworthy news coverage, informative perspectives on cross-strait relations, plus inspiring lifestyle content focusing on food, travel and entertainment. Proud to be based in one of Asia's most vibrant democracies, our diverse team of journalists and producers is committed to delivering independent news and stories that inform, enlighten and inspire audiences worldwide. Get a global perspective backed by a Taiwanese point of view on our website, mobile app, TV channel and various social media channels. About Fuji TVFuji Television Network, Inc. (Fuji TV) is one of Japan's leading broadcasters, renowned for its innovative entertainment, high-quality drama, cutting-edge news, and cultural programming. Since its founding in 1957, Fuji TV has been a pioneer in shaping Japan's media landscape, creating content that resonates with audiences both domestically and internationally. With a strong commitment to creativity and global collaboration, Fuji TV continues to deliver compelling stories and experiences across multiple platforms, including television, film, digital, and live events.
The global launch of 'BT21 X FRAGMENT' collection brings together Hiroshi Fujiwara's streetwear brand 'FRAGMENT' and the globally beloved character IP 'BT21,' creating a chic and hip styles Expressing the edgy sophistication of BT21's all-black transformation through FRAGMENT collaboration, the collection features not only fashion apparel like hoodies and fleece jackets but also irresistibly stylish digital accessories such as keyrings, badges, and reusable bags Following the collection's first successful pop-up opening in Seoul, Korea, grabbing the attention of Gen Z fashion lovers, the collection is also scheduled to be available in the US, Japan, Taiwan, and Hong Kong in December SEOUL, South Korea, Dec. 1, 2023 /PRNewswire/ -- The digital IP entertainment company, IPX (formerly known as LINE FRIENDS) has launched the highly anticipated collaboration collection, 'BT21 X FRAGMENT.' Through this unique collaboration with the widely influential streetwear designer Hiroshi Fujiwara's brand 'FRAGMENT,' the globally beloved character IP 'BT21' has turned into a hip fashion icon. The collection will be available worldwide in the United States, Japan, Taiwan, and Hong Kong in December. BT21 X FRGMT Collaboration Created by the renowned designer, producer, and musician Hiroshi Fujiwara, FRAGMENT's distinct lightning logo and contemporary designs have garnered acclaim in the global street fashion scene through collaborations with prestigious global brands. This collaboration with BT21 showcases a new facet of the characters, as they embrace a sleek and hip all-black look, departing from their previous adorable image. Presenting BT21 characters with the iconic lightning logo of FRAGMENT, the exclusive 'BT21 X FRAGMENT' collection features a range of stylish and trendy fashion items, from hoodies, caps, and fleece jackets to plushies, keyrings, badges, and smartphone cases. The collaboration has captivated global fashion enthusiasts, catering to the diverse tastes of Generation Z. The collection was pre-released on November 20th on the South Korea's limited-edition trading platform, KREAM, where all the pre-released amount sold out rapidly with a high competition for the draw, attesting to its popularity online prior to the official launch. Building on this success, a pop-up store has been unveiled on November 30th in Seoul, Korea, marking the collection's official premiere. The store grabbed the attention of the Generation Z, attracting a long line of visitors on its opening day. Following Korea, the collection embarks on a global tour through online platforms and offline pop-ups in the United States, Japan, Taiwan, and Hong Kong in December. The IPX officials said, "Having collaborated with brands like Dr. Martens and Converse, BT21 now presents a unique collaboration with the distinctive street fashion brand FRAGMENT. We hope this collection, embodying the charm of BT21 as a hip fashion icon, becomes a must-have item for fashion lovers worldwide." About IPX (F.K.A LINE FRIENDS) IPX is the new corporate name of LINE FRIENDS, a global character brand that originally started from Original Characters including BROWN, CONY, SALLY created for use as stickers for the leading mobile messenger app LINE and its 200 million active users worldwide. IPX recently announced a new business strategy that it would accelerate the global expansion of its IP businesses by diversifying its IP portfolios targeting all ages and advancing its digital and retail business. IPX has carried out its IP-based business by partnering with global companies including Netflix (original animated series), SUPERCELL (Brawl Stars), and NEXON (KartRider), while it has created popular IPs including digital artist 'WADE', 'BT21' (BTS), 'TRUZ' (Treasure) and broadened their boundaries to virtual influencers to win the hearts of over 40 million Millennials and Generation Z worldwide. IPX currently operates in 17 markets worldwide including Seoul, New York, LA, Tokyo, and Shanghai, and operates in 16 online sales platforms.
TAIPEI, July 1, 2024 /PRNewswire/ -- This is a report from Sunrisemedium: BE Health, a hospital venture capital and accelerator, is entering the Japanese market. The company aims to connect biomedical startups with the market needs in Taiwan and Japan. Through this connection, BE Health is building an international MedTech startup-supporting ecosystem to expand the business opportunities in the Asia-Pacific region. It is not easy for biomedical startups to establish relationships with hospitals. Thus, biomedical startups trudging through forming partnerships compares to the other industries. The medical field, closely linked to human life, operates under stringent regulations and complex industry standards, making caution and multi-level validation a norm within the medical field. Many believe that obtaining regulatory approval for new drugs and innovative medical devices is the most challenging hurdle, such as gaining certification from the FDA (Food and Drug Administration) of the United States. However, those familiar with the biomedical industry know that identifying whether a startup idea addresses an "Unmet Clinical Need" is much more critical and significantly requires substantial effort. At least medical institutions and physicians should recognize this startup idea as an issue. On the other hand, if a startup cannot access validation sites, even substantial funding may be insufficient. Biomedical innovation also has a unique characteristic of variability in clinical applications. Different doctors may have different approaches, leading to scenarios where one physician struggles with an issue that another handles effortlessly. No matter which country, biomedical startups face an uphill battle from the outset. Biomedical startups have a set of challenges, including proof of concept, product testing, and regulatory reviews after overcoming initial hurdles. The fledgling startups have few resources and time to navigate these obstacles. Thus, the United States can dominate biomedical innovation because of its well-developed medical history and abundant resources. Though the Asian-Pacific region nurtures many biotech talents, it still faces significant challenges in promoting biomedical startups due to its fragmented markets, complex cultural differences, and regulatory discrepancies across countries. Hospital-Supported Venture Capital Increases Success Rates for Biotech Startups Biomedical accelerators are created precisely for this purpose. This approach takes inspiration from the United States, where the Mayo Clinic, a top hospital, established its venture capital department as early as 1968. The department aimed to shorten the lengthy process from problem identification and solution discovery to validation and commercialization in frontline medical settings. BE Health Accelerator is rooted in Taiwan and has spent six to seven years forging collaborations with Taipei Medical University (TMU), Show Chwan Health Care System, and Kaohsiung Medical University (KMU). BE Health establishes its venture capital fund and integrates resources by forming a biomedical startup-supporting ecosystem: Venture Captials + Accelerators + Hospitals. With this ecosystem, BE Health supports over 140 Taiwan and overseas biotech startups and directly invests in nearly 30 teams. This approach has reduced the commercialization progress from 7-8 years to 3-5 years. Arthur Chen, Founder & Managing Partner at BE Health, emphasized "Medical devices only sell if doctors are willing to use them," highlighting the critical factor for success. Arthur Chen, Founder & Managing Partner at BE Health The most fundamental economic theory is supply and demand. As biomedical science is a highly specialized and often inaccessible field to the general public, early validation is the shortest path to determining demand. BE Health provides opportunities for startups and doctors to work together clinically through its collaboration with Taipei Medical University, Show Chwan Health Care System, and Kaohsiung Medical University. This collaboration quickly allows startup teams to connect with key persons in their respective fields and obtain firsthand confirmation of whether their medical devices meet the needs of doctors. Point Robotics MedTech Inc. focuses on minimally invasive medical equipment development. Once Point Robotics leveraged BE Health's accelerator program to connect with Jacques Marescaux, a renowned French surgeon known for his innovative surgical techniques and methods with IRCAD Taiwan Show Chwan Asian Institute of TeleSurgery. This connection facilitated discussions on medical concepts and initiated subsequent clinical trials at IRCAD Taiwan. Taiwan is ideally suited for developing biomedical products, particularly for early validation of medical devices. Four key advantages of Taiwan help startups overcome various obstacles and achieve commercialization and market integration more quickly. High Density of Multidisciplinary Talent: Taiwan boasts a wealth of talent in technology and healthcare, making cross-disciplinary collaboration easier. "We have a rich concentration of resources in a small area, not just in healthcare but also in hardware, software, and engineering," said Arthur Chen. Comprehensive Supply Chain: "From Keelung to Wugu, you can find all the suppliers you need in just one day," Chen noted, highlighting Taiwan's complete supply chain that allows companies to quickly and easily find production partners. Extensive Medical Database: Benefiting from Taiwan's National Health Insurance system, which features a single-payer format, Taiwan can compile and standardize medical data, addressing the challenge of data accessibility. Entrepreneurial DNA: Chen humorously remarked on the strong entrepreneurial spirit of the Taiwanese people. Despite being a small island, Taiwan is a treasure trove of talent, resources, and innovation. Taiwan-Japan Collaboration Expands International Business Opportunities Any startups that complete initial product validation in Taiwan must move towards the international market due to Taiwan's limited population. In the transition to the global market, BE Health plays a crucial role. "We position ourselves as the 'Gateway to Asia,' leading teams onto the international stage to gain global recognition," stated Arthur Chen, Founder & Managing Partner at BE Health. Chen has identified Japan as the first target market. Japan is the world's fourth-largest economy and has a population of 125 million. These characteristics make Japan represent a significant challenge in the Asia-Pacific region. If a startup can successfully navigate the Japanese market imply the startup is capable of further expanding into European and American markets. The Japanese biomedical market is ranked third globally and shares institutional compatibility with Taiwan through historical ties. "Japanese built National Taiwan University Hospital," Chen noted, emphasizing the shared medical education heritage. This foundation facilitates familiarity and cooperation between medical professionals in both regions. The well-connected relationships in traditional medical practices can hardly transition to the innovative startup era. It requires time for innovation to take root in the Japanese conservative and hierarchical medical system with its cultural norms. BE Health supports Taiwanese biomedical startups in navigating these cultural shocks during their market entry into Japan. For instance, resource-stapped startups often feel frustrated about the hierarchical reporting structure in Japan's medical system that demands consensus-building at every level before escalating issues to the final decision maker. To address these challenges, BE Health has designed mentorship programs to help startups accommodate local customs and integrate smoothly into the Japanese market. "The initial goal of establishing the accelerator was to identify promising international teams and bring advanced medical technologies to Japan. In that case, we can expand business opportunities within Japan's vast domestic market," explained Chen. Beyond cultural integration, the ultimate challenge for biomedical startups is achieving the "Gold Standard." "Attaining the Gold Standard is vital," Chen emphasized. The people in the medical field must meticulously follow the standard procedures because it is associated with human lives. Each medical startup must overcome critical and daunting tasks to gain professional recognition and sufficient validation. BE Health has extensive experience in support teams through demand validation and regulatory guidance to ensure the startups meet these rigorous standards. BE Health Provides the Premier Biotech Startup Acceleration Ecosystem in the Asia-Pacific Market BE Health holds a unique strategic position between Taiwan and Japan even though it is not the only biotech accelerator. "Most accelerators do not have direct partnerships with hospitals. In this case, those accelerators must start from scratch to get the medical resources of hospitals. In contrast, our hospital venture resources extend from the medical side outward. Therefore, we can offer a head start to the startups we mentor or invest in," explained Chen. BE Health has directly collaborated with Taiwanese medical institutions. It allows BE Health to integrate into the conventional networks of the Taiwanese and Japanese medical communities and to form connections with Tohoku University Hospital, Japan's third-largest, and partnerships with the medical system of Tokyo University. This strategic positioning offers startups immediate access to the core Japanese medical market. Arthur Chen chose a distinctive focus on biomedical venture capital six years ago when he started his business. He has the blueprint of creating a "multinational & multi-center" for the biomedical field to integrate the Asia-Pacific market. Taiwan boasts strong capabilities in both software and hardware. Since BE Health started aligning with the Japanese market, BE Health aims to advance cross-countries clinical trials to build multinational & multi-center regulation. With this approach, advanced startups supported by BE Health can apply their results across different countries and save time and costs of redundant validations. "We hope that in the future, all of Asia, including Taiwan, Japan, Singapore, and China, can deepen the cooperation in their markets," said Chen. Japan represents the first step in this multinational, multi-center blueprint. Thus, BE Health plans to engage in a series of events, including a business exchange with Startup Island TAIWAN in Kansai in early July, hosting a Demoday in Taiwan at the end of July, and leading the team to participate in Medical Japan Tokyo in October. Moreover, BE Health is preparing to establish a local accelerator in Japan. Arthur Chen has seen the Japanese healthcare market as robust and well-regulated with comprehensive insurance. Chen believes that biotech startups with good technology, products, and talent can leverage the transnational network resources built by BE Health. Therefore, these startups can rapidly integrate into the core markets of the Asia-Pacific biotech industry. Japan is close to Taiwan, just a movie away from Taipei to Tokyo. At the same time, it is also distant for teams with no guidance to get into the Japanese market. BE Health serves as a bridge, embodying the essence of its Mandarin name, "比翼 (bi-yi)," linking venture capitals with startups and enabling them to fly highly together in the biomedical field.
Concurrent SessionsSEA Conference 2024 by The Malaysian Water Association (MWA)Business Forums from Singapore and Japan KUALA LUMPUR, Malaysia, Oct. 15, 2024 /PRNewswire/ -- Sustainability Environment Asia (SEA) will stage a bigger comeback in its upcoming second edition from 12 to 14 November 2024 to meet the demand for circular solutions and expedite cross-border partnerships towards net zero and decarbonisation. SUSTAINABILITY ENVIRONMENT ASIA (SEA) 2024 TO SPUR GREEN PROGRESS AND CROSS-BORDER PARTNERSHIPS The three-day event will be an innovative showcase of environmental innovations, expert discussions and a series of forums designed to drive business and partnerships under the theme "Driving Innovations for a Sustainable Circular Economy". Sub-themes presented on the exhibition floor will include sustainable energy solutions, waste management and circular economy, water and sewerage, green environmental and technology. Networking opportunities will be further boosted by a conference hosted by Supporting Partner, The Malaysian Water Association (MWA), and business forums by key stakeholders from Singapore and Japan. Deputy Prime Minister Yang Amat Berhormat Dato' Sri Haji Fadillah Yusof, who is also Minister of Energy Transition and Water Transformation (PETRA), is scheduled to officiate the show on 13 November 2024. Similar to last year, SEA will take place alongside E-Mobility Asia (EMA) at the Kuala Lumpur Convention Centre. Both events are organised by Derrisen Sdn Bhd. The two shows will feature 100 international exhibitors from eight countries and regions and welcome an expected 12,000 trade visitors. Delegations from India, Indonesia, Japan, Philippines, Singapore, South Korea, Taiwan, Thailand are expected to attend the show. The diversity provides the perfect opportunity for businesses to connect for business ideas and opportunities in tackling sustainable development. The SEA Conference 2024 on 13 November by MWA will focused on ESG and water topics, featuring a special session titled " Regional Water Forum: Transforming Water Towards a Sustainable Future", bringing together speakers from ASEAN Water Associations. It will kick off with a keynote by Mr. Charles Santiago, Chairman of National Water Service Commission (SPAN) on the topic "Sustainability Concerns for Malaysia's Water Services: What's Relevant, What to do and When?" and followed by a Regional Water Forum with a panel of ASEAN speakers. "As the Supporting Partner, MWA aims to highlight the importance of the water sector in sustainable development and policy. Challenges in our industry present opportunities for innovation, collaboration, and relationship-building, which are the key themes of SEA 2024. The conference organised by MWA will share knowledge, raise awareness on sustainability issues, and encourage the adoption of innovative solutions, fostering meaningful collaborations to shape a sustainable future for our water and environmental enterprises," said Dr. Ir. Ts. Hj. Mohmad Asari Daud, President of MWA. Singapore Water Association (SWA) returns with a pavilion showcasing 10 companies and it will also conduct a pre-show site visit to a local sewerage and water treatment plant. "As representatives of SWA, we believe that SEA 2024 aligns perfectly with the growing sustainability awareness in Malaysia. SWA is committed to fostering innovation and positioning Singapore as a global leader in the water industry. This year, we are organising the second edition of Singapore Business Forum and Business Matching and to bring companies to exhibit under the Singapore Pavilion. Through collaboration with SEA, our goal is to showcase innovative solutions that drive sustainability in Southeast Asia," said Ms. Vivien Seong, Executive Director, SWA. Japan's Ministry of Land, Infrastructure, Transport and Tourism (MLIT) will hold business forum and business matching on 12 November 2024 to highlight trends and opportunities in sustainability. It is anticipated that approximately 10 Japanese companies will attend the forum. More sharing and networking opportunities can be found in the Women in Sustainability 2.0 Forum, following on its inaugural success last year, and at the series of technical seminars by exhibitors. A key highlight is the Networking Night for SEA and EMA participants on the second day to engage more prospects and collaboration opportunities. "SEA will continue to drive new frontiers in sustainable development by bringing together the solutions, people and the partnerships which can make the difference. We are more than just a trade show organiser, we are also committed to advancing a future of environmental responsibility. I wish to thank all partners, from Malaysia and overseas, who have come forward to support the show this year," said Ms. Vicky Tan, Project Director at Derrisen. SEA 2024 is endorsed by several government ministries and agencies -- Ministry of Energy Transition and Water Transformation (PETRA), Ministry of Investment, Trade and Industry (MITI), Ministry of Housing and Local Government (KPKT), and Malaysia External Trade Development Corporation (MATRADE) which provides enhanced tax incentives and double tax deductions for export promotion. (For more information, please visit www.matrade.gov.my) Supporting Partner: The Malaysian Water Association (MWA) Supporting Agencies: Suruhanjaya Perkhidmatan Air Negara (SPAN), Suruhanjaya Tenaga (ST), Sustainable Energy Development Authority (SEDA) Local Supporting Associations: ESG Association of Malaysia (ESGAM), Malaysian Recycling Alliance (MAREA), Small and Medium Enterprises Association (SAMENTA), and The Electrical and Electronic Association of Malaysia (TEEAM) International Supporting Associations: Philippine Water Works Association (PWWA), Singapore Water Association (SWA), Taiwan Drinking Water Equipment Association (TDWA), Taiwan Environmental Manufacturers Association (TEMA) and Vietnam Water Supply and Sewerage Association (VWSA) For more information on exhibiting opportunities and visitor registration, visit https://sustainabilityenvironmentasia.com/. Notes to Editors Derrisen is a specialist in delivering impactful trade events and conferences for businesses and industries to create sustainable high performance and growth. We bring you a deeply passionate and experienced team of organisers to deliver leading industry and lifestyle portfolios in Southeast Asia to help our clients achieve their business goals and shared purpose of building positive relationships for long-term success.
A12 藝術空間
Taiwan-Japan collaboration
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
